The Impact of THC and CBD in Schizophrenia: A Systematic Review.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed, 52 citations in OpenAlex.

1. Randomized Laboratory Study of Single-Dose Cannabis, Dronabinol, and Placebo in Patients With Schizophrenia and Cannabis Use Disorder.Schizophrenia bulletin · 2025
   Trial
2. Psychiatric effects of cannabidiol, cannabinol, and tetrahydrocannabinol: A narrative review of clinical evidence and risk profiles.PCN reports : psychiatry and clinical neurosciences · 2026
   Review
3. Envisioning Cannabinoid CB1 Receptor Biased Signaling as a Therapeutic Target for Schizophrenia.The American journal of psychiatry · 2026
   Review
4. Elucidating the Complex Etiology of Schizophrenia: Comprehensive Insights into the Therapeutic Roles of Natural Compounds and Pharmacological Interventions.Current pharmaceutical design · 2026
   Review
5. The Relationship Between Cannabis Use and Schizophrenia As a Risk Factor or For Its Therapeutic Potential: A Systematic Review of Evidence.Cureus · 2025
   Review
6. Tobacco, Alcohol, and Drug Use Among Young Adults with Serious Mental Illness.Community mental health journal · 2024
   Article
7. The Role of Cannabis in the Development of Psychosis.Turk psikiyatri dergisi = Turkish journal of psychiatry · 2024
   Review
8. Differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen.Frontiers in psychiatry · 2024
   Review
9. Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta-analysis on 3053 individuals.EClinicalMedicine · 2023
   Article
10. The Main Therapeutic Applications of Cannabidiol (CBD) and Its Potential Effects on Aging with Respect to Alzheimer's Disease.Biomolecules · 2023
    Review
11. Therapeutic Potential of Cannabis: A Comprehensive Review of Current and Future Applications.Biomedicines · 2023
    Review
12. Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review.Behavioural neurology · 2023
    Review
13. European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists · 2022
    Review
14. Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia.CNS drugs · 2022
    Review
15. Alternative Therapy of Psychosis: Potential Phytochemicals and Drug Targets in the Management of Schizophrenia.Frontiers in pharmacology · 2022
    Review
16. Understanding the Potential Benefits of Cannabidiol for Patients With Schizophrenia: A Narrative Review.Schizophrenia bulletin open · 2022
    Article
17. A Cannabinoid Hypothesis of Schizophrenia: Pathways to Psychosis.Innovations in clinical neuroscience
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors at 2 institutions in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as